• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Idiopathic hypersomnia symptoms over Time: Longitudinal follow up from the Hypersomnia Foundation registry.特发性嗜睡症症状随时间的变化:来自嗜睡症基金会登记处的纵向随访
Sleep Med. 2025 Sep;133:106627. doi: 10.1016/j.sleep.2025.106627. Epub 2025 Jun 1.
2
A Patient-centric Clinical Trial Design to Comprehensively Evaluate Low-Sodium Oxybate in People with Idiopathic Hypersomnia or Narcolepsy.一项以患者为中心的临床试验设计,旨在全面评估低钠羟丁酸钠在发作性睡病或特发性过度睡眠患者中的疗效。
Neurol Ther. 2025 Jun 9. doi: 10.1007/s40120-025-00745-7.
3
A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia.发作性睡病中睡眠惯性视觉模拟量表的最小临床重要差异。 (注:原文标题中的“Idiopathic hypersomnia”应改为“Narcolepsy”才准确,即发作性睡病,这里按照原文翻译)
J Clin Sleep Med. 2025 Jul 1;21(7):1209-1216. doi: 10.5664/jcsm.11662.
4
Insights from a 10-year Australasian idiopathic hypersomnia patient data registry study.一项为期10年的澳大拉西亚特发性发作性睡病患者数据登记研究的见解。
J Clin Sleep Med. 2024 Dec 1;20(12):1955-1964. doi: 10.5664/jcsm.11298.
5
Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.肌强直性营养不良患者嗜睡(白天过度嗜睡)的精神兴奋剂。
Cochrane Database Syst Rev. 2024 Nov 18;11(11):CD003218. doi: 10.1002/14651858.CD003218.pub3.
6
Pharmacotherapy for anxiety and comorbid alcohol use disorders.焦虑症合并酒精使用障碍的药物治疗
Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007505. doi: 10.1002/14651858.CD007505.pub2.
7
Pharmacotherapies for sleep disturbances in dementia.痴呆症睡眠障碍的药物治疗
Cochrane Database Syst Rev. 2016 Nov 16;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub3.
8
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
9
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
10
Psychological therapies for women who experience intimate partner violence.针对遭受亲密伴侣暴力的女性的心理疗法。
Cochrane Database Syst Rev. 2020 Jul 1;7(7):CD013017. doi: 10.1002/14651858.CD013017.pub2.

本文引用的文献

1
Absence of dysregulation in amplitude and phase of circadian rhythm of core body temperature in idiopathic hypersomnia: a case-control study.特发性发作性睡病患者核心体温昼夜节律的幅度和相位无失调:一项病例对照研究。
Sleep. 2025 Mar 11;48(3). doi: 10.1093/sleep/zsae246.
2
Psychiatric comorbidity in Danish patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia: a case-control study.丹麦1型发作性睡病、2型发作性睡病和特发性嗜睡症患者的精神共病:一项病例对照研究。
Sleep Adv. 2024 Oct 5;5(1):zpae073. doi: 10.1093/sleepadvances/zpae073. eCollection 2024.
3
Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial.莫达非尼与安非他命右旋苯丙胺治疗特发性嗜睡症和 2 型发作性睡病的随机、双盲、非劣效性试验。
CNS Drugs. 2024 Nov;38(11):909-920. doi: 10.1007/s40263-024-01122-y. Epub 2024 Sep 21.
4
Insights from a 10-year Australasian idiopathic hypersomnia patient data registry study.一项为期10年的澳大拉西亚特发性发作性睡病患者数据登记研究的见解。
J Clin Sleep Med. 2024 Dec 1;20(12):1955-1964. doi: 10.5664/jcsm.11298.
5
Validation and performance of the sleep inertia questionnaire in central disorders of hypersomnolence.睡眠惯性问卷在中枢性嗜睡障碍中的验证和性能。
Sleep Med. 2024 Sep;121:352-358. doi: 10.1016/j.sleep.2024.07.024. Epub 2024 Jul 23.
6
Clinical considerations in the treatment of idiopathic hypersomnia.特发性嗜睡症治疗的临床注意事项。
Sleep Med. 2024 Jul;119:488-498. doi: 10.1016/j.sleep.2024.05.013. Epub 2024 May 7.
7
Prevalence and Course of Idiopathic Hypersomnia in the Wisconsin Sleep Cohort Study.特发性嗜睡症在威斯康星睡眠队列研究中的患病率和病程。
Neurology. 2024 Jan 23;102(2):e207994. doi: 10.1212/WNL.0000000000207994. Epub 2023 Dec 13.
8
Idiopathic hypersomnia years after the diagnosis.诊断多年后的特发性嗜睡症。
J Sleep Res. 2024 Apr;33(2):e14011. doi: 10.1111/jsr.14011. Epub 2023 Aug 12.
9
Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia.特发性嗜睡症成人安慰剂对照、双盲、随机撤药研究的开放性扩展期内低钠羟丁酸钠的长期疗效和安全性。
J Clin Sleep Med. 2023 Oct 1;19(10):1811-1822. doi: 10.5664/jcsm.10698.
10
Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion.特发性嗜睡症治疗进展:进展、挑战和专家意见。
Sleep Med Rev. 2023 Jun;69:101766. doi: 10.1016/j.smrv.2023.101766. Epub 2023 Feb 25.

特发性嗜睡症症状随时间的变化:来自嗜睡症基金会登记处的纵向随访

Idiopathic hypersomnia symptoms over Time: Longitudinal follow up from the Hypersomnia Foundation registry.

作者信息

Chattaraj Audrika, Freeman Amanda A, Nichols Kendall J, Ong Jason C, Plante David T, Saini Prabhjyot, Murray Catherine Friederich, King Rebecca, Bliwise Donald L, Trotti Lynn Marie

机构信息

Emory University, Atlanta, GA, USA.

Center for the Study of Human Health, Emory University, Atlanta, GA, USA.

出版信息

Sleep Med. 2025 Sep;133:106627. doi: 10.1016/j.sleep.2025.106627. Epub 2025 Jun 1.

DOI:10.1016/j.sleep.2025.106627
PMID:40472564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12335360/
Abstract

INTRODUCTION

Limited data are available regarding the long-term course of idiopathic hypersomnia. We analyzed longitudinal data from the Hypersomnia Foundation Registry at CoRDS to evaluate changes in symptoms and medication usage over time.

METHODS

Registry participants reporting a diagnosis of idiopathic hypersomnia were included if they completed the registry questionnaire at least twice, with at least six months before first and last questionnaire. Responses were analyzed using paired t-test for continuous variables and McNemar test for categorical variables, comparing first and last responses.

RESULTS

Data from three hundred twenty-three participants were included, with a mean age 35.0 ± 12.2 and 86.5 % women. Average time between first and last response was 2.4 ± 1.4 years. Symptoms remained largely stable over the 2 ½ year period, with persistent difficulty awakening (in 78.7 % at baseline and 73.0 % at follow up), daytime sleepiness (62.7 % and 61.8 %), trouble waking up and functioning with normal alertness (56.4 % and 56.4 %), requiring multiple alarms (53.4 % and 55.3 %), brain fog (46.3 % and 48.4 %), and memory problems (42.7 % and 43.4 %). Average nightly sleep duration on workdays and non-workdays and average nap duration were all stable over time. Participants made an average of 0.8 ( ± 1.1) medication changes, with most (55.4 %) participants remaining on the same medications. Comorbid mood disorders were relatively common, with a modest increase in anxiety diagnoses.

CONCLUSIONS

Symptoms of idiopathic hypersomnia remained relatively stable over an average of 2.4 years of follow up. Despite persistent symptoms being experienced by the majority of participants, medication changes were infrequent.

摘要

引言

关于特发性嗜睡症的长期病程,可用数据有限。我们分析了CoRDS的嗜睡症基金会登记处的纵向数据,以评估症状和药物使用随时间的变化。

方法

如果登记参与者报告患有特发性嗜睡症诊断,并且至少完成两次登记调查问卷,且第一次和最后一次调查问卷之间至少间隔六个月,则将其纳入研究。对于连续变量,使用配对t检验分析回答;对于分类变量,使用McNemar检验分析回答,比较第一次和最后一次回答。

结果

纳入了323名参与者的数据,平均年龄为35.0±12.2岁,女性占86.5%。第一次和最后一次回答之间的平均时间为2.4±1.4年。在2.5年的时间里,症状基本保持稳定,持续存在觉醒困难(基线时为78.7%,随访时为73.0%)、日间嗜睡(62.7%和61.8%)、醒来困难且难以正常清醒地运作(56.4%和56.4%)、需要多个闹钟(53.4%和55.3%)、脑雾(46.3%和48.4%)以及记忆问题(42.7%和43.4%)。工作日和非工作日的平均夜间睡眠时间以及平均午睡时间随时间均保持稳定。参与者平均进行了0.8(±1.1)次药物调整,大多数(55.4%)参与者仍使用相同的药物。共病情绪障碍相对常见,焦虑症诊断略有增加。

结论

在平均2.4年的随访中,特发性嗜睡症的症状相对稳定。尽管大多数参与者持续出现症状,但药物调整并不频繁。